The majority of RARS and RCMD-RS have mutations in SF3B1, and these cases have a better outcome compared with cases without the mutation. SF3B1 mutants also have a high percentage of mutations involving DNA methylation genes. In wild-type SF3B1, those with mutations in other splicing genes also segregate with DNA methylation mutations, whereas those with no RNA splicing mutations have a higher prevalence of TP53 mutations. The figure has been adapted from data and Figure 2C in the article by Malcovati et al that begins on page 233.